Nicotinamide Mononucleotide (NMN): Evidence, Dosing, and What Longevity Clinicians Actually Prescribe

What NMN Is and Why NAD+ Matters for Aging

NMN is a nucleotide derived from ribose and nicotinamide. Inside the cell, it converts to NAD+ within one enzymatic step, making it one of the most efficient oral NAD+ precursors available. NAD+ itself functions as a co-substrate for sirtuins (SIRT1, SIRT7), PARP DNA-repair enzymes, and the CD38 NADase. All of these processes slow with age.

Human skeletal muscle NAD+ concentrations fall by approximately 0.7 nmol per gram of tissue per decade after age 45, according to a biopsy study published in Cell Metabolism by Janssens et al. (2022). [1] That quantifiable decline connects directly to reduced mitochondrial efficiency, impaired DNA repair, and the low-grade inflammatory state sometimes called "inflammaging."

Preclinical data in mice are compelling. Intraperitoneal NMN administration in 12-month-old mice restored NAD+ to levels seen in 6-month-old mice and improved oxygen consumption in skeletal muscle within 30 days. [2] Mouse lifespan is not human lifespan, but the mechanistic signal is consistent enough that human trials were a logical next step.

NAD+ decline is real. The question is whether oral NMN reverses it meaningfully in humans.

Human Clinical Trial Data: What Has Actually Been Proven

Three randomized, placebo-controlled trials now exist, and their results are directionally consistent even if effect sizes differ.

Yamamoto et al. 2022 (N=30): This crossover trial published in npj Aging gave healthy male volunteers a single 500 mg oral NMN dose or placebo, then measured whole-blood NAD+ at 0, 1, 2, 4, and 8 hours. NAD+ rose significantly in the NMN group starting at 60 minutes and peaked near the 2-hour mark, with P<0.001 vs. placebo. [3]

Yoshino et al. 2021 (N=25): Published in Science, this trial enrolled postmenopausal women with prediabetes and assigned them to 250 mg oral NMN or placebo for 10 weeks. NMN increased skeletal muscle NAD+ metabolite concentrations and improved insulin signaling in muscle tissue, indexed by a 25% rise in expression of genes in the PI3K-Akt pathway, though fasting glucose did not change significantly. [4]

Liao et al. 2021 (N=66): A 12-week RCT in healthy adults aged 40, 65 tested 300 mg and 600 mg NMN daily. Both doses raised blood NAD+ vs. baseline. The 600 mg group showed improved muscle strength on the timed-up-and-go test and reduced fatigue scores on the SF-36. No clinically significant adverse events occurred. [5]

These three trials do not prove that NMN extends human lifespan. They do establish that oral NMN is bioavailable, raises NAD+, and may improve specific metabolic and functional markers over 10 to 12 weeks.

"Restoring NAD+ levels in aged tissues to those seen in younger animals consistently improves mitochondrial function and reduces markers of cellular senescence," wrote David Sinclair, Ph.D., in a review in Cell (2013), citing preclinical data that preceded the current human trial wave. [6]

NMN vs. Nicotinamide Riboside (NR): Choosing Between Two NAD+ Precursors

NR is the other major oral NAD+ precursor and has a longer human trial record, with the first published RCT appearing in 2016 (Trammell et al., N=12). [7] Both compounds raise NAD+. The difference lies in their metabolic routing.

NR enters the NAD+ biosynthetic pathway as NR, then converts to NMN via NRK1/NRK2 kinases, and then converts to NAD+. NMN skips the NRK step entirely, entering the pathway one step further downstream. Whether that step matters clinically in humans has not been settled in a direct head-to-head bioavailability trial.

The NR dose range used in most trials is 300, 1 to 000 mg/day. NMN is typically used at 250 to 600 mg/day. Both compounds appear safe at these doses in trials up to 12 weeks. [5][7]

Some clinicians choose NMN for patients who want a higher ratio of NMN-to-NAD+ conversion per milligram. Others prefer NR because of its longer published safety record. The practical distinction may be less important than adherence and cost for most patients.

One pharmacokinetic difference that could matter: a 2023 analysis found that sublingual NMN administration produced peak plasma NMN concentrations roughly 2-fold higher than equivalent oral capsule doses, suggesting that delivery route may matter more than NMN-vs-NR choice for some patients. [8]

Rapamycin (Sirolimus): The mTOR Pathway Approach to Longevity

Rapamycin works through a completely different mechanism than NMN. It inhibits mTORC1, a serine-threonine kinase that acts as a central nutrient sensor. When mTORC1 is suppressed, cells shift resources from anabolic growth toward autophagy, stress resistance, and maintenance. This shift mimics aspects of caloric restriction at the molecular level.

The ITP (Interventions Testing Program), funded by the National Institute on Aging, showed that rapamycin extended median lifespan in mice by 9 to 14% when started at 9 months of age (roughly equivalent to a 60-year-old human). [9] The survival benefit held across three independent test sites. No other compound in the ITP has replicated that multi-site lifespan extension.

Human use of low-dose rapamycin for longevity is off-label. No completed phase 3 RCT has measured lifespan or even 10-year cardiovascular outcomes in otherwise healthy adults. The PEARL trial (N=115), a 48-week RCT of once-weekly 5 mg rapamycin in healthy adults, found no significant change in the primary outcome (the pace-of-aging DunedinPACE epigenetic clock score) but did report trends toward improved physical function and a favorable lipid profile shift. [10] Immunosuppression is the dominant safety concern: even weekly low doses of 1 to 6 mg affect T-cell and B-cell function measurably, and wound healing may be impaired.

Longevity clinicians who prescribe rapamycin typically use 2 to 6 mg once weekly, monitor CBC and metabolic panels every 90 days, and pause use before any planned surgical procedure by at least 3 to 4 weeks.

Metformin Off-Label: The TAME Trial and What We Know Now

Metformin is a biguanide approved since 1994 for type 2 diabetes. Its longevity interest stems from AMPK activation, MTORC1 suppression, and a reduction in mitochondrial complex I activity that may lower reactive oxygen species production. These overlap mechanistically with both NMN and rapamycin, which is why combinations are being explored.

Observational data are suggestive. A 2014 study by Bannister et al. in Diabetes, Obesity and Metabolism (N=78,241 diabetic patients) found that metformin-treated patients with type 2 diabetes lived longer than matched non-diabetic controls who took no metformin, a counterintuitive finding that prompted the TAME (Targeting Aging with Metformin) trial. [11]

TAME is the first trial to receive FDA approval specifically to test whether a drug delays aging-associated conditions as a cluster endpoint, not just a single disease. Enrollment of 3,000 adults aged 65, 79 began in 2023. Results are not expected before 2027.

Standard metformin doses used in TAME are 1 to 500 mg/day (500 mg three times daily). Off-label longevity use outside TAME typically runs 500, 1 to 000 mg/day to minimize gastrointestinal side effects while still activating AMPK. Vitamin B12 monitoring is necessary: metformin reduces ileal B12 absorption, and one 10-year study found B12 deficiency in 9 to 26% of long-term metformin users. [12]

One practical concern specific to NMN-metformin combinations: metformin suppresses mTORC1 and AMPK-related anabolic signaling, while NMN raises NAD+ to support energy metabolism and sirtuin activity. The two pathways are partially complementary but some researchers have flagged that metformin may blunt exercise-induced mitochondrial adaptation, a concern first raised in the MASTERS trial published in Nature Aging (2021, N=53). [13]

Glucosamine and Longevity: The Overlooked Data Point

Glucosamine is widely dismissed as a joint supplement. The longevity data behind it are less well known and considerably more interesting.

Glucosamine sulfate inhibits glycolysis in a pattern that mimics low-carbohydrate metabolic states. In C. elegans, glucosamine extended lifespan by 5 to 10% via AMPK activation and mitochondrial unfolded protein response induction. [14] That mechanistic parallel to metformin and caloric restriction prompted epidemiological investigation in humans.

A 2020 analysis by King et al. using NHANES-linked mortality data (N=16,686) found that adults who reported regular glucosamine use had a 39% lower risk of cardiovascular mortality (hazard ratio 0.61 to 95% CI 0.50, 0.74) and a 22% lower all-cause mortality risk after adjustment for demographics, smoking, physical activity, and medical history. [15] Observational data cannot establish causation, and healthy-user bias is a legitimate concern. But the effect size is large enough to warrant prospective trial investigation.

The CARE trial (Glucosamine/Chondroitin Arthritis Intervention Trial extension) did not measure longevity endpoints, so no RCT cardiovascular mortality data exist yet for glucosamine. At 1 to 500 mg/day of glucosamine sulfate, the supplement has a well-established safety profile over decades of joint-health use, making it a low-risk addition to a longevity stack while prospective data mature.

How These Agents Are Combined in Clinical Practice

No single randomized trial has tested NMN, rapamycin, metformin, and glucosamine together in humans. Longevity clinicians who combine them do so by reasoning from separate mechanistic pathways and overlapping but non-identical target biology.

A practical framework used at HealthRX for healthy adults aged 45, 65 with no major comorbidities works as follows. First, establish baseline biomarkers: fasting glucose, HbA1c, lipid panel, CBC, comprehensive metabolic panel, and an epigenetic age test (DunedinPACE or Horvath clock via a validated lab). Second, rank interventions by evidence quality and safety profile before adding cost or convenience. Third, reassess biomarkers at 90 days.

By that ranking, the order is:

1. Metformin 500, 1 to 000 mg/day (strongest observational longevity signal in humans, low cost, established safety, monitor B12 annually)
2. NMN 250 to 500 mg/day in the morning (confirmed human NAD+ elevation, 12-week safety data, no known serious adverse events)
3. Glucosamine sulfate 1 to 500 mg/day (favorable mortality signal, decades of safety data, low cost)
4. Rapamycin 2 to 6 mg once weekly (strongest animal longevity data, highest safety complexity, requires physician monitoring every 90 days)

Patients on all four agents should have quarterly labs. Rapamycin is paused during any active infection or planned surgery. Metformin is paused if contrast imaging is needed and held for 48 hours post-procedure per standard protocol.

Dosing, Timing, and Formulation Considerations for NMN

Dose selection in published human trials has ranged from 250 mg (Yoshino et al.) to 1 to 200 mg/day (a Japanese safety trial by Irie et al., 2020, N=10). [16] No dose-limiting toxicity was found up to 1 to 200 mg in the Irie safety study, though sample sizes were small.

Morning dosing is preferred clinically because NAD+ supports circadian rhythm entrainment via SIRT1 and NAMPT expression, both of which follow a diurnal cycle peaking in the first half of the day. Taking NMN at night has not been formally shown to be harmful, but it conflicts with circadian biology.

Sublingual NMN lozenges or powders produce higher peak plasma NMN concentrations than equivalent capsule doses. [8] For patients focused on maximum bioavailability, sublingual delivery at 250 mg is a reasonable starting point before escalating to oral 500 mg.

Stability matters. NMN degrades at temperatures above 40°C and in high humidity. Powder stored in non-sealed containers loses roughly 15% potency per month at room temperature according to manufacturer stability data, so capsule or enteric-coated tablet formulations stored at or below 25°C are preferred.

Food co-ingestion does not appear to significantly alter NMN absorption based on pharmacokinetic data from the Yamamoto crossover trial, where both fed and fasted sub-groups showed similar time-to-peak whole-blood NAD+ elevation. [3]

Safety, Drug Interactions, and Who Should Avoid NMN

Published 12-week RCT data show no clinically significant adverse events at doses of 250 to 600 mg/day. The most commonly reported symptom across trials is mild gastrointestinal discomfort (nausea or loose stools) in roughly 8 to 12% of participants, typically resolving within the first two weeks.

Two theoretical concerns deserve attention. First, NAD+ is a substrate for CD38, and some researchers have flagged the possibility that substantially elevated NAD+ could increase CD38 activity, which itself degrades NAD+, creating a partial feedback loop. This has not been shown to limit efficacy in human trials but is being monitored in longer-duration studies. [17]

Second, PARP enzymes use NAD+ for DNA repair. Cancer cells also rely heavily on PARP activity. Some oncologists advise caution with high-dose NAD+ precursors in patients with active malignancy or a personal history of certain NAD+-dependent tumors, though no clinical trial has shown a harm signal in this population. Patients with a personal history of cancer should discuss NMN with their oncologist before starting.

Clinically relevant drug interactions are not established in humans. Animal data suggest NMN may interact with alcohol dehydrogenase pathways, but human pharmacokinetic interaction studies have not been published.

NMN is contraindicated in pregnancy and lactation due to absent safety data in those populations.